Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$18.66 -4.4%	$22.07	$15.47 ▼ $36.37	$667.49M	1.17	238,524 shs	304,192 shs
GNFT GENFIT	$3.82 -2.9%	$3.98	$2.55 ▼ $6.42	$196.76M	1.14	2,827 shs	2,836 shs
IOVA Iovance Biotherapeutics	$2.68 +4.3%	$2.14	$1.64 ▼ $12.51	$858.21M	0.87	25.14 million shs	16.65 million shs
VIR Vir Biotechnology	$5.03 -0.8%	$5.30	$4.32 ▼ $14.45	$700.87M	1.18	1.08 million shs	809,884 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-4.36%	-11.90%	-11.56%	-12.39%	-14.79%
GNFT GENFIT	-0.52%	-1.55%	+0.26%	-10.86%	-9.38%
IOVA Iovance Biotherapeutics	+4.28%	-14.38%	+53.14%	-23.43%	-69.30%
VIR Vir Biotechnology	-0.79%	-10.97%	-7.37%	-18.34%	-50.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.6362 of 5 stars	4.6	0.0	0.0	0.6	0.8	0.0
GNFT GENFIT	1.7154 of 5 stars	3.5	3.0	0.0	1.9	0.0	0.0
IOVA Iovance Biotherapeutics	4.4649 of 5 stars	4.2	1.0	4.2	2.5	4.2	0.6
VIR Vir Biotechnology	2.8821 of 5 stars	3.4	1.0	0.0	2.4	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	110.53% Upside
GNFT GENFIT	3.00	Buy	$13.00	240.76% Upside
IOVA Iovance Biotherapeutics	2.33	Hold	$12.22	356.05% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	501.39% Upside

Current Analyst Ratings Breakdown

Latest GNFT, AVBP, VIR, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/22/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
GNFT GENFIT	$76.77M	2.48	$0.07 per share	56.26	$1.50 per share	2.54
IOVA Iovance Biotherapeutics	$164.07M	5.45	N/A	N/A	$2.33 per share	1.15
VIR Vir Biotechnology	$74.21M	9.37	N/A	N/A	$8.35 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/7/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	8/6/2025 (Confirmed)

Latest GNFT, AVBP, VIR, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	N/A	N/A	N/A	$67.14 million	N/A
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	$2.38 million	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
GNFT GENFIT	0.08	1.23	1.23
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
GNFT GENFIT	2.24%
IOVA Iovance Biotherapeutics	77.03%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
GNFT GENFIT	4.20%
IOVA Iovance Biotherapeutics	10.30%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

GNFT, AVBP, VIR, and IOVA Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1 at 3:10 AM | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31 at 7:23 PM | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31 at 9:31 AM | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31 at 8:05 AM | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31 at 4:40 AM | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31 at 4:33 AM | marketbeat.com

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 30 at 11:07 AM | zacks.com

Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours

July 26, 2025 | pharmabiz.comP

First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525

July 25, 2025 | finance.yahoo.com

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 24, 2025 | businesswire.com

Vir Biotechnology: Hep B And Cancer Projects March On

July 23, 2025 | seekingalpha.com

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in Stock

July 18, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in Stock

July 18, 2025 | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of Stock

July 18, 2025 | insidertrades.com

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025 | finance.yahoo.com

Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation

July 12, 2025 | msn.com

Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

July 10, 2025 | zacks.com

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?

July 9, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets

GNFT, AVBP, VIR, and IOVA Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$18.66 -0.85 (-4.36%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.67 +0.01 (+0.05%)

As of 08/1/2025 04:04 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

GENFIT NASDAQ:GNFT

$3.82 -0.12 (-2.93%)

As of 08/1/2025 03:58 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Iovance Biotherapeutics NASDAQ:IOVA

$2.68 +0.11 (+4.28%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.75 +0.07 (+2.46%)

As of 08/1/2025 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Vir Biotechnology NASDAQ:VIR

$5.03 -0.04 (-0.79%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.17 +0.14 (+2.86%)

As of 08/1/2025 04:16 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time